Our anti-cancer drug screening highlighted several compounds targeting signaling pathways associated with the oncogenic mechanisms of RELAFUS1, such as RTK, HDAC and NF-κB inhibitors including a proteasome inhibitor. This evidence concerns the gene HDAC9 and cancer.